Biomea Fusion, Inc. (BMEA) EBITDA
- 2026-06-30: Basis Reported; EBITDA (m); Operating income -$12.77M; Depreciation and amortization (m).
- 2026-03-31: Basis Reported; EBITDA (m); Operating income -$12.77M; Depreciation and amortization (m).
- 2025-09-30: Basis Reported; EBITDA (m); Operating income -$20.80M; Depreciation and amortization (m).
- 2025-06-30: Basis Reported; EBITDA (m); Operating income -$21.28M; Depreciation and amortization (m).
Historical EBITDA
EBITDA 3 month
| Date | Basis | EBITDA | Operating income | Depreciation and amortization | Revenue | EBITDA margin | Capital spending | Operating cash flow | Cost of products and services | Research and development | Selling, general and administration | Income tax expense / benefit |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | Reported | (m) | -$12.77M | (m) | (m) | (m) | (m) | -$10.03M* | (m) | $9.14M | (m) | (m) |
| 2026-03-31 | Reported | (m) | -$12.77M | (m) | (m) | (m) | (m) | -$11.67M | (m) | $9.12M | (m) | (m) |
| 2025-09-30 | Reported | (m) | -$20.80M | (m) | (m) | (m) | $0.00* | -$11.55M* | (m) | $14.40M | (m) | (m) |
| 2025-06-30 | Reported | (m) | -$21.28M | (m) | (m) | (m) | $0.00* | -$19.21M* | (m) | $16.57M | (m) | (m) |
| 2025-03-31 | Reported | (m) | -$29.71M | (m) | (m) | (m) | $0.00 | -$25.67M | (m) | $22.90M | (m) | (m) |
| 2024-12-31 | Reported | (m) | -$30.07M | (m) | (m) | (m) | (m) | (m) | (m) | $25.24M | (m) | (m) |
| 2024-09-30 | Reported | (m) | -$34.04M | (m) | (m) | (m) | $186.00K* | -$25.22M* | (m) | $27.24M | (m) | (m) |
| 2024-06-30 | Reported | (m) | -$38.90M | (m) | (m) | (m) | $59.00K* | -$32.64M* | (m) | $31.82M | (m) | (m) |
| 2024-03-31 | Reported | (m) | -$41.06M | (m) | (m) | (m) | $35.00K | -$32.03M | (m) | $33.78M | (m) | (m) |
| 2023-12-31 | Reported | (m) | -$37.33M | (m) | (m) | (m) | (m) | (m) | (m) | $30.87M | (m) | (m) |
| 2023-09-30 | Reported | (m) | -$31.12M | (m) | (m) | (m) | $39.00K* | -$23.90M* | (m) | $25.35M | (m) | (m) |
| 2023-06-30 | Reported | (m) | -$27.66M | (m) | (m) | (m) | $417.00K* | -$25.81M* | (m) | $21.94M | (m) | (m) |
| 2023-03-31 | Reported | (m) | -$30.03M | (m) | (m) | (m) | $2.91M | -$24.04M | (m) | $24.39M | (m) | (m) |
| 2022-12-31 | Reported | (m) | -$26.28M | (m) | (m) | (m) | (m) | (m) | (m) | $20.54M | (m) | (m) |
| 2022-09-30 | Reported | (m) | -$23.48M | (m) | (m) | (m) | -$50.00K* | -$16.80M* | (m) | $18.24M | (m) | (m) |
| 2022-06-30 | Reported | (m) | -$17.47M | (m) | (m) | (m) | $273.00K* | -$15.43M* | (m) | $12.58M | (m) | (m) |
| 2022-03-31 | Reported | (m) | -$16.40M | (m) | (m) | (m) | $95.00K | -$9.99M | (m) | $11.35M | (m) | (m) |
| 2021-12-31 | Reported | (m) | -$14.74M | (m) | (m) | (m) | (m) | (m) | (m) | $11.09M | (m) | (m) |
| 2021-09-30 | Reported | (m) | -$12.64M | (m) | (m) | (m) | $2.04M* | -$8.99M* | (m) | $7.89M | (m) | (m) |
| 2021-06-30 | Reported | (m) | -$8.44M | (m) | (m) | (m) | $771.00K* | -$6.48M* | (m) | $5.22M | (m) | (m) |
| 2021-03-31 | Reported | (m) | -$5.86M | (m) | (m) | (m) | $67.00K | -$4.08M | (m) | $3.80M | (m) | (m) |
| 2020-12-31 | Reported | (m) | -$3.50M | (m) | (m) | (m) | (m) | (m) | (m) | $2.33M | (m) | (m) |
| 2020-09-30 | Reported | (m) | -$1.14M | (m) | (m) | (m) | (m) | -$1.10M* | (m) | $789.00K | (m) | (m) |
| 2020-06-30 | Reported | (m) | -$295.00K | (m) | (m) | (m) | (m) | -$369.00K* | (m) | $216.00K | (m) | (m) |
| 2020-03-31 | Reported | (m) | -$398.00K | (m) | (m) | (m) | (m) | -$252.00K | (m) | $334.00K | (m) | (m) |
EBITDA 12 month
| Date | Basis | EBITDA | Operating income | Depreciation and amortization | Revenue | EBITDA margin | Capital spending | Operating cash flow | Cost of products and services | Research and development | Selling, general and administration | Income tax expense / benefit |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-12-31 | Reported | (m) | -$83.51M | (m) | (m) | (m) | (m) | -$70.37M | (m) | $61.98M | (m) | $0.00 |
| 2025-09-30 | Rolling | (m) | -$101.87M* | (m) | (m) | (m) | (m) | (m) | (m) | $79.10M* | (m) | (m) |
| 2025-06-30 | Rolling | (m) | -$115.10M* | (m) | (m) | (m) | (m) | (m) | (m) | $91.95M* | (m) | (m) |
| 2025-03-31 | Rolling | (m) | -$132.72M* | (m) | (m) | (m) | (m) | (m) | (m) | $107.21M* | (m) | (m) |
| 2024-12-31 | Reported | (m) | -$144.07M | (m) | (m) | (m) | $362.00K | -$119.89M | (m) | $118.08M | (m) | $0.00 |
| 2024-12-31 | Rolling | (m) | -$144.07M* | (m) | (m) | (m) | (m) | (m) | (m) | $118.08M* | (m) | (m) |
| 2024-09-30 | Rolling | (m) | -$151.32M* | (m) | (m) | (m) | (m) | (m) | (m) | $123.71M* | (m) | (m) |
| 2024-06-30 | Rolling | (m) | -$148.40M* | (m) | (m) | (m) | (m) | (m) | (m) | $121.81M* | (m) | (m) |
| 2024-03-31 | Rolling | (m) | -$137.16M* | (m) | (m) | (m) | (m) | (m) | (m) | $111.93M* | (m) | (m) |
| 2023-12-31 | Reported | (m) | -$126.14M | (m) | (m) | (m) | $3.37M | -$96.59M | (m) | $102.55M | (m) | $0.00 |
| 2023-12-31 | Rolling | (m) | -$126.14M* | (m) | (m) | (m) | (m) | (m) | (m) | $102.55M* | (m) | (m) |
| 2023-09-30 | Rolling | (m) | -$115.08M* | (m) | (m) | (m) | (m) | (m) | (m) | $92.22M* | (m) | (m) |
| 2023-06-30 | Rolling | (m) | -$107.45M* | (m) | (m) | (m) | (m) | (m) | (m) | $85.11M* | (m) | (m) |
| 2023-03-31 | Rolling | (m) | -$97.27M* | (m) | (m) | (m) | (m) | (m) | (m) | $75.76M* | (m) | (m) |
| 2022-12-31 | Reported | (m) | -$83.63M | (m) | (m) | (m) | $1.03M | -$62.42M | (m) | $62.71M | (m) | $0.00 |
| 2022-12-31 | Rolling | (m) | -$83.63M* | (m) | (m) | (m) | (m) | (m) | (m) | $62.71M* | (m) | (m) |
| 2022-09-30 | Rolling | (m) | -$72.09M* | (m) | (m) | (m) | (m) | (m) | (m) | $53.26M* | (m) | (m) |
| 2022-06-30 | Rolling | (m) | -$61.25M* | (m) | (m) | (m) | (m) | (m) | (m) | $42.91M* | (m) | (m) |
| 2022-03-31 | Rolling | (m) | -$52.21M* | (m) | (m) | (m) | (m) | (m) | (m) | $35.55M* | (m) | (m) |
| 2021-12-31 | Reported | (m) | -$41.67M | (m) | (m) | (m) | $3.17M | -$35.44M | (m) | $28.00M | (m) | $0.00 |
| 2021-12-31 | Rolling | (m) | -$41.67M* | (m) | (m) | (m) | (m) | (m) | (m) | $28.00M* | (m) | (m) |
| 2021-09-30 | Rolling | (m) | -$30.43M* | (m) | (m) | (m) | (m) | (m) | (m) | $19.24M* | (m) | (m) |
| 2021-06-30 | Rolling | (m) | -$18.93M* | (m) | (m) | (m) | (m) | (m) | (m) | $12.14M* | (m) | (m) |
| 2021-03-31 | Rolling | (m) | -$10.79M* | (m) | (m) | (m) | (m) | (m) | (m) | $7.13M* | (m) | (m) |
| 2020-12-31 | Reported | (m) | -$5.33M | (m) | (m) | (m) | $51.00K | -$4.46M | (m) | $3.67M | (m) | $0.00 |
| 2020-12-31 | Rolling | (m) | -$5.33M* | (m) | (m) | (m) | (m) | (m) | (m) | $3.67M* | (m) | (m) |
| 2019-12-31 | Reported | (m) | -$1.20M | (m) | (m) | (m) | (m) | -$1.28M | (m) | $1.09M | (m) | (m) |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Polaryx Therapeutics, Inc. (PLYX) | United States | $0.106B | |
| Equillium, Inc. (EQ) | United States | $0.109B | -11.27 |
| GENELUX Corp (GNLX) | United States | $0.110B | -3.83 |
| BICYCLE THERAPEUTICS PLC (BCYC) | $0.112B | -1.56 | |
| ProMIS Neurosciences Inc. (PMN) | $0.102B | ||
| Quantum Cyber N.V. (QUCY) | $0.113B | ||
| Immuneering Corp (IMRX) | United States | $0.113B | -12.51 |
| Milestone Pharmaceuticals Inc. (MIST) | $0.098B | -2.00 | |
| CITIUS ONCOLOGY, INC. (CTOR) | United States | $0.097B | -1.49 |
| Anixa Biosciences Inc (ANIX) | United States | $0.096B |